A PHASE II TRIAL EVALUATING THE COMBINATION OF ERIBULIN (HALAVEN) + BEVACIZUMAB (AVASTIN) AS A FIRST LINE TREATMENT IN PATIENTS WITH METASTATIC HER2- BREAST CANCER

Trial Profile

A PHASE II TRIAL EVALUATING THE COMBINATION OF ERIBULIN (HALAVEN) + BEVACIZUMAB (AVASTIN) AS A FIRST LINE TREATMENT IN PATIENTS WITH METASTATIC HER2- BREAST CANCER

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms ESMERALDA
  • Most Recent Events

    • 11 Oct 2016 Results of this study, presented at the 41st European Society for Medical Oncology Congress.
    • 16 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 14 Jan 2015 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top